[ad_1]
Hu Z, Ott PA, Wu CJ. In the direction of personalised, tumour-specific, therapeutic vaccines for most cancers. Nat Rev Immunol. 2018;18:168–82.
Melero I, Gaudemack G, Gerritsen W, Huber C, Parmiani G, Scholl S, et al. Therapeutic vaccines for most cancers: an outline of scientific trials. Nat Rev Clin Onco. 2014;11(9):509–24.
Melief CJM, van Corridor T, Arens R, Ossendorp F, van der Burg SH. Therapeutic most cancers vaccines. J Clin Investig. 2015;125(9):3401–12.
Man B. The right combine: current progress in adjuvant analysis. Nat Rev Microbiol. 2007;5(7):505–17.
Reed SG, Orr MT, Fox CB. Key roles of adjuvants in trendy vaccines. Nat Med. 2013;19(12):1597–608.
Palucka Okay, Banchereau J. Most cancers immunotherapy through dendritic cells. Nat Rev Most cancers. 2012;12(4):265–77.
Chen W, Zuo H, Li B, Duan C, Rolfe B, Zhang B, et al. Clay nanoparticles elicit long-term immune responses by forming biodegradable depots for sustained antigen stimulation. Small. 2018;14(19):e1704465.
Verbeke CS, Mooney DJ. Injectable, Pore-forming hydrogels for in vivo enrichment of immature dendritic cells. Adv Healthc Mater. 2015;4(17):2677–87.
Zhang L-X, Solar X-M, Jia Y-B, Liu X-G, Dong M, Xu ZP, et al. Nanovaccine’s speedy induction of anti-tumor immunity considerably improves malignant most cancers immunotherapy. Nano Immediately. 2020;35:100923.
Zhu G, Zhang F, Ni Q, Niu G, Chen X. Environment friendly nanovaccine supply in most cancers immunotherapy. ACS Nano. 2017;11(3):2387–92.
von Andrian UH, Mempel TR. Homing and mobile visitors in lymph nodes. Nat Rev Immunol. 2003;3(11):867–78.
Itano AA, Jenkins MK. Antigen presentation to naive CD4 T cells within the lymph node. Nat Immunol. 2003;4(8):733–9.
Irvine DJ, Hanson MC, Rakhra Okay, Tokatlian T. Artificial nanoparticles for vaccines and immunotherapy. Chem Rev. 2015;115(19):11109–46.
Moyer TJ, Zmolek AC, Irvine DJ. Past antigens and adjuvants: formulating future vaccines. J Clin Make investments. 2016;126(3):799–808.
Milling L, Zhang Y, Irvine DJ. Delivering safer immunotherapies for most cancers. Adv Drug Deliv Rev. 2017;114:79–101.
Jiang H, Wang Q, Solar X. Lymph node concentrating on methods to enhance vaccination efficacy. J Management Launch. 2017;267:47–56.
Ding Y, Li Z, Jaklenec A, Hu Q. Vaccine supply programs towards lymph nodes. Adv Drug Deliv Rev. 2021. https://doi.org/10.1016/j.addr.2021.113914.
Howard GP, Verma G, Ke X, Thayer WM, Hamerly T, Baxter VK, et al. Crucial measurement restrict of biodegradable nanoparticles for enhanced lymph node trafficking and paracortex penetration. Nano Res. 2019;12(4):837–44.
Fan Y, Moon JJ. Nanoparticle drug supply programs designed to enhance most cancers vaccines and immunotherapy. Vaccines. 2015;3(3):662–85.
Chen F, Wang Y, Gao J, Saeed M, Li T, Wang W, et al. Nanobiomaterial-based vaccination immunotherapy of most cancers. Biomaterials. 2021;270:120709.
Liu G, Zhu M, Zhao X, Nie G. Nanotechnology-empowered vaccine supply for enhancing CD8+ T cells-mediated mobile immunity. Adv Drug Deliv Rev. 2021;176:113889.
Schudel A, Francis DM, Thomas SN. Materials design for lymph node drug supply. Nat Rev Mater. 2019;4(6):415–28.
Music T, Xia Y, Du Y, Chen MW, Qing H, Ma G. Engineering the deformability of albumin-stabilized emulsions for lymph-node vaccine supply. Adv Mater. 2021;33(26):e2100106.
Yang W, Deng H, Zhu S, Lau J, Tian R, Wang S, et al. Measurement-transformable antigen-presenting cell-mimicking nanovesicles potentiate efficient most cancers immunotherapy. Sci Adv. 2020;6(50):eabd1631.
Zhang L-X, Jia Y-B, Huang Y-R, Liu H-N, Solar X-M, Cai T, et al. Environment friendly supply of clay-based nanovaccines to the mouse spleen promotes potent anti-tumor immunity for each prevention and therapy of lymphoma. Nano Res. 2021;14(5):1326–34.
Li S, Feng X, Wang J, Xu W, Islam MA, Solar T, et al. Multiantigenic nanoformulations activate anticancer immunity relying on measurement. Adv Funct Mater. 2019;29(49):1903391.
Kim J, Li WA, Choi Y, Lewin SA, Verbeke CS, Dranoff G, et al. Injectable, spontaneously assembling, inorganic scaffolds modulate immune cells in vivo and improve vaccine efficacy. Nat Biotecy. 2015;33(1):64–72.
Mao C, Gorbet MJ, Singh A, Ranjan A, Fiering S. In situ vaccination with nanoparticles for most cancers immunotherapy: understanding the immunology. Int J Hyperthermia. 2020;37(3):4–17.
Wang H, Mooney DJ. Biomaterial-assisted focused modulation of immune cells in most cancers therapy. Nat Mater. 2018;17(9):761–72.
Gu W, Bobrin VA, Chen SPR, Wang Z, Schoning JP, Gu Y, et al. Biodistribution of PNIPAM-coated nanostructures Synthesized by the TDM methodology. Biomacromol. 2018;20(2):625–34.
Han X, Shen SF, Fan Q, Chen GJ, Archibong E, Dotti G, et al. Pink blood cell-derived nanoerythrosome for antigen supply with enhanced most cancers immunotherapy. Sci Adv. 2019;5(10):eaaw6870.
den Haan JM, Martinez-Pomares L. Macrophage heterogeneity in lymphoid tissues. Semin Immunopathol. 2013;35(5):541–52.
Tavares AJ, Poon W, Zhang Y-N, Dai Q, Besla R, Ding D, et al. Impact of eradicating Kupffer cells on nanoparticle tumor supply. Proc Natl Acad Sci U S A. 2017;114(51):E10871–80.
Nikitin MP, Zelepukin IV, Shipunova VO, Sokolov IL, Deyev SM, Nikitin PI. Enhancement of the blood-circulation time and efficiency of nanomedicines through the compelled clearance of erythrocytes. Nat Biomed Eng. 2020;4(7):717–31.
Schudel A, Chapman AP, Yau MK, Higginson CJ, Francis DM, Manspeaker MP, et al. Programmable multistage drug supply to lymph nodes. Nat Nanotechnol. 2020;15(6):491–9.
Girard JP, Moussion C, Förster R. HEVs, Lymphatics and homeostatic immune cell trafficking in lymph nodes. Nat Rev Immunol. 2012;12(11):762–73.
Kuai R, Ochyl LJ, Bahjat KS, Schwendeman A, Moon JJ. Designer vaccine nanodiscs for personalised most cancers immunotherapy. Nat Mater. 2017;16(4):489–96.
Hu Z, Ott PA, Wu CJ. In the direction of personalised, tumour-specific, therapeutic vaccines for most cancers. Nat Rev Immunol. 2018;18(3):168–82.
Marcandalli J, Fiala B, Ols S, Perotti M, de van der Schueren W, Snijder J, et al. Induction of potent neutralizing antibody responses by a designed protein nanoparticle vaccine for respiratory syncytial virus. Cell. 2019;176(6):1420–31.
Min Y, Roche KC, Tian S, Eblan MJ, McKinnon KP, Caster JM, et al. Antigen-capturing nanoparticles enhance the abscopal impact and most cancers immunotherapy. Nat Nanotechnol. 2017;12(9):877–82.
Yang W, Zhu G, Wang S, Yu G, Yang Z, Lin L, et al. In situ dendritic cell vaccine for efficient most cancers immunotherapy. ACS Nano. 2019;13(3):3083–94.
Zhang Y, Poon W, Sefton E, Chan WCW. Suppressing subcapsular sinus macrophages enhances transport of nanovaccines to lymph node follicles for sturdy humoral immunity. ACS Nano. 2020;14(8):9478–90.
Kool M, Fierens Okay, Lambrecht BNJJ. Alum adjuvant: a few of the tips of the oldest adjuvant. J Med Microbiol. 2012;61(7):927–34.
Gupta RK, Relyveld EH, Lindblad EB, Bizzini B, Ben-Efraim S, Gupta CKJV. Adjuvants—a stability between toxicity and adjuvanticity. Vaccine. 1993;11(3):293–306.
Zhang LX, Xie XX, Liu DQ, Xu ZP, Liu RT. Environment friendly co-delivery of neo-epitopes utilizing dispersion-stable layered double hydroxide nanoparticles for enhanced melanoma immunotherapy. Biomaterials. 2018;174:54–66.
Xu C, Hong H, Lee Y, Park KS, Solar M, Wang T, et al. Environment friendly lymph node-targeted supply of personalised most cancers vaccines with reactive oxygen species-inducing diminished graphene oxide nanosheets. ACS Nano. 2020;14(10):13268–78.
Yin Y, Li X, Ma H, Zhang J, Yu D, Zhao R, et al. In situ reworking RNA nanovaccines from polyethylenimine functionalized graphene oxide hdrogel for sturdy most cancers immunotherapy. Nano Lett. 2021;21(5):2224–31.
Moore JE Jr, Bertram CD. Lymphatic system flows. Annu Rev Fluid Mech. 2018;50:459–82.
Margaris KN, Black RA. Modelling the lymphatic system: challenges and alternatives. J R Soc Interface. 2012;9(69):601–12.
Bachmann MF, Jennings GT. Vaccine supply: a matter of measurement, geometry, kinetics and molecular patterns. Nat Rev Immunol. 2010;10(11):787–96.
Gong N, Zhang Y, Zhang Z, Li X, Liang X-J. Purposeful nanomaterials optimized to avoid tumor immunological tolerance. Adv Funct Mater. 2019;29(3):1806087.
Swartz MA. The physiology of the lymphatic system. Adv Drug Deliv Rev. 2001;50(1–2):3–20.
Reddy ST, Rehor A, Schmoekel HG, Hubbell JA, Swartz MA. In vivo concentrating on of dendritic cells in lymph nodes with poly(propylene sulfide) nanoparticles. J Management Launch. 2006;112(1):26–34.
Oussoren C, Zuidema J, Crommelin DJ, Storm G. Lymphatic uptake and biodistribution of liposomes after subcutaneous injection. II. Affect of liposomal measurement, lipid compostion and lipid dose. Biochem Biophys Acta. 1997;1328(2):261–72.
Leak LV. Research on the permeability of lymphatic capillaries. J Cell Biol. 1971;50(2):300–23.
Oberli MA, Reichmuth AM, Dorkin JR, Mitchell MJ, Fenton OS, Jaklenec A, et al. Lipid nanoparticle assisted mRNA supply for potentcCancer immunotherapy. Nano Lett. 2017;17(3):1326–35.
Karabin NB, Allen S, Kwon HK, Bobbala S, Firlar E, Shokuhfar T, et al. Sustained micellar supply through inducible transitions in nanostructure morphology. Nat Commun. 2018;9(1):624.
Cho NH, Cheong TC, Min JH, Wu JH, Lee SJ, Kim D, et al. A multifunctional core-shell nanoparticle for dendritic cell-based most cancers immunotherapy. Nat Nanotechnol. 2011;6(10):675–82.
Pflicke H, Sixt M. Preformed portals facilitate dendritic cell entry into afferent lymphatic vessels. J Exp Med. 2009;206(13):2925–35.
Manolova V, Flace A, Bauer M, Schwarz Okay, Saudan P, Bachmann MF. Nanoparticles goal distinct dendritic cell populations in response to their measurement. Eur J Immunol. 2008;38(5):1404–13.
Li F, Chen Y, Liu S, Pan X, Liu Y, Zhao H, et al. The impact of measurement, dose, and administration route on zein nanoparticle immunogenicity in BALB/c mice. Int J Nanomedicine. 2019;14:9917–28.
Chen W, Zhang B, Mahony T, Gu W, Rolfe B, Xu ZP. Environment friendly and sturdy vaccine towards intimin beta of diarrheagenic E. coli induced by clay nanoparticles. Small. 2016;12(12):1627–39.
Singh M, Chakrapani A, O’Hagan D. Nanoparticles and microparticles as vaccine-delivery programs. Knowledgeable Rev Vaccines. 2007;6(5):797–808.
Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational strategy to more practical vaccines. Curr Mol Med. 2007;7(2):143–55.
Xia Y, Wu J, Wei W, Du Y, Wan T, Ma X, et al. Exploiting the pliability and lateral mobility of Pickering emulsion for enhanced vaccination. Nat Mater. 2018;17(2):187–94.
Hammerich L, Binder A, Brody JD. In situ vaccination: Most cancers immunotherapy each personalised and off-the-shelf. Mol Oncol. 2015;9(10):1966–81.
Zhang LX, Solar XM, Xu ZP, Liu RT. Growth of multifunctional clay-based nanomedicine for elimination of major invasive breast most cancers and prevention of its lung metastasis and distant inoculation. ACS Appl Mater Interfaces. 2019;11(39):35566–76.
Chu Y, Liu Q, Wei J, Liu B. Personalised most cancers neoantigen vaccines come of age. Theranostics. 2018;8(15):4238–46.
Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, et al. Neoantigen panorama dynamics throughout human melanoma-T cell interactions. Nature. 2016;536(7614):91–5.
Schumacher TN, Schreiber RD. Neoantigens in most cancers immunotherapy. Science. 2015;348(6230):69–74.
Liu J, Li HJ, Luo YL, Xu CF, Du XJ, Du JZ, et al. Enhanced major tumor penetration facilitates nanoparticle draining into lymph nodes after systemic injection for tumor metastasis inhibition. ACS Nano. 2019;13(8):8648–58.
Wang S, Li F, Ye T, Wang J, Lyu C, Qing S, et al. Macrophage-tumor chimeric exosomes accumulate in lymph node and tumor to activate the immune response and the tumor microenvironment. Sci Transl Med. 2021;13(615):eabb6981.
Wang Y, Gong N, Ma C, Zhang Y, Tan H, Qing G, et al. An amphiphilic dendrimer as a light-activable immunological adjuvant for in situ most cancers vaccination. Nat Commun. 2021;12(1):4964.
Chen W, Qin M, Chen X, Wang Q, Zhang Z, Solar X. Combining photothermal remedy and immunotherapy towards melanoma by polydopamine-coated Al2O3 nanoparticles. Theranostics. 2018;8(8):2229–41.
Noy R, Pollard JW. Tumor-associated macrophages: from mechanisms to remedy. Immunity. 2014;41(1):49–61.
Cooks T, Pateras IS, Jenkins LM, Patel KM, Robles AI, Morris J, et al. Mutant p53 cancers reprogram macrophages to tumor supporting macrophages through exosomal miR-1246. Nat Commun. 2018;9(1):771.
Corbet C, Feron O. Tumour acidosis: from the passenger to the driving force’s seat. Nat Rev Most cancers. 2017;17(10):577–93.
Chen Q, Wang C, Zhang X, Chen G, Hu Q, Li H, et al. In situ sprayed bioresponsive immunotherapeutic gel for post-surgical most cancers therapy. Nat Nanotechnol. 2019;14(1):89–97.
An J, Zhang Okay, Wang B, Wu S, Wang Y, Zhang H, et al. Nanoenabled disruption of a number of obstacles in antigen cross-presentation of dendritic cells through calcium interference for enhanced chemo-immunotherapy. ACS Nano. 2020;14(6):7639–50.
Jiang L, Jung S, Zhao J, Kasinath V, Ichimura T, Joseph J, et al. Simultaneous concentrating on of major tumor, draining lymph node, and distant metastases via excessive endothelial venule-targeted supply. Nano Immediately. 2021;36:101045.
Marchesi VT, Gowans JL. The migration of lymphocytes via the endothelium of venules in lymph nodes: an electron microscope stud. Proc R Soc Lond B Biol Sci. 1964;159:283–90.
Mondino A, Khoruts A, Jenkins MK. The anatomy of T-cell activation and tolerance. Proc Natl Acad Sci U S A. 1996;93(6):2245–52.
Cyster JG. B cell follicles and antigen encounters of the third variety. Nat Immunol. 2010;11(11):989–96.
Willard-Mack CL. Regular construction, operate, and histology of lymph nodes. Toxicol Pathol. 2006;34(5):409–24.
Phan TG, Inexperienced JA, Grey EE, Xu Y, Cyster JG. Immune advanced relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol. 2009;10(7):786–93.
Phan TG, Grigorova I, Okada T, Cyster JG. Subcapsular encounter and complement-dependent transport of immune complexes by lymph node B cells. Nat Immunol. 2007;8(9):992–1000.
Junt T, Moseman EA, Iannacone M, Massberg S, Lang PA, Boes M, et al. Subcapsular sinus macrophages in lymph nodes clear lymph-borne viruses and current them to antiviral B cells. Nature. 2007;450(7166):110–4.
Gonzalez SF, Degn SE, Pitcher LA, Woodruff M, Heesters BA, Carroll MC. Trafficking of B cell antigen in lymph nodes. Annu Rev Immunol. 2011;29:215–33.
Kuka M, Iannacone M. Viral subversion of B cell responses inside secondary lymphoid organs. Nat Rev Immunol. 2018;18(4):255–65.
Carrasco YR, Batista FD. B cells purchase particulate antigen in a macrophage-rich space on the boundary between the follicle and the subcapsular sinus of the lymph node. Immunity. 2007;27(1):160–71.
Qin H, Zhao R, Qin Y, Zhu J, Chen L, Di C, et al. Growth of a most cancers vaccine utilizing in vivo click-chemistry-mediated lively lymph node accumulation for improved immunotherapy. Adv Mater. 2021;33(20):e2006007.
Wang L, He Y, He T, Liu G, Lin C, Li Okay, et al. Lymph node-targeted immune-activation mediated by imiquimod-loaded mesoporous polydopamine based-nanocarriers. Biomaterials. 2020;255:120208.
Sultan H, Kumai T, Nagato T, Wu J, Salazar AM, Celis E. The route of administration dictates the immunogenicity of peptide-based most cancers vaccines in mice. Most cancers Immunol Immunother. 2019;68(3):455–66.
Bronte V, Pittet MJ. The spleen in native and systemic regulation of immunity. Immunity. 2013;39(5):806–18.
Kranz LM, Diken M, Haas H, Kreiter S, Loquai C, Reuter KC, et al. Systemic RNA supply to dendritic cells exploits antiviral defence for most cancers immunotherapy. Nature. 2016;534(7607):396–401.
Liu J, Zhang R, Xu ZP. Nanoparticle-Primarily based Nanomedicines to advertise most cancers immunotherapy: current advances and future instructions. Small. 2019;15:e1900262.
Moghimi SM, Hedeman H, Muir IS, Illum L, Davis SS. An Investigation of the filtration capability and the destiny of huge filtered sterically-stabilized microspheres in rat spleen. Biochem Biophys Acta. 1993;1157(3):233–40.
Moghimi SM, Hunter AC, Andresen TL. Elements controlling nanoparticle pharmacokinetics: an built-in evaluation and perspective. In: Insel PA, Amara SG, Blaschke TF, editors. Annu Rev Pharmacol Toxicol, Vol 52. Annu Rev Pharmacol Toxicol. 522012. p. 481–503.
Cataldi M, Vigliotti C, Mosca T, Cammarota M, Capone D. Rising function of the spleen within the pharmacokinetics of monoclonal antibodies, nanoparticles and exosomes. Int J Mol Sci. 2017;18(6):1249.
Demoy M, Andreux JP, Weingarten C, Gouritin B, Guilloux V, Couvreur P. In vitro analysis of nanoparticles spleen seize. Life Sci. 1999;64(15):1329–37.
Ernsting MJ, Murakami M, Roy A, Li S-D. Elements controlling the pharmacokinetics, biodistribution and intratumoral penetration of nanoparticles. J Management Launch. 2013;172(3):782–94.
Ouyang B, Poon W, Zhang Y-N, Lin ZP, Kingston BR, Tavares AJ, et al. The dose threshold for nanoparticle tumour supply. Nat Mater. 2020;19(12):1362–71.
Peng F, Setyawati MI, Tee JK, Ding X, Wang J, Nga ME, et al. Nanoparticles promote in vivo breast most cancers cell intravasation and extravasation by inducing endothelial leakiness. Nat Nanotech. 2019;14(3):279–86.
Ukidve A, Zhao Z, Fehnel A, Krishnan V, Pan DC, Gao Y, et al. Erythrocyte-driven immunization through biomimicry of their pure antigen-presenting operate. Proc Natl Acad Sci U S A. 2020;117(30):17727–36.
Zhang Y, Wu JLY, Lazarovits J, Chan WCW. An evaluation of the binding operate and structural group of the protein corona. J Am Chem Soc. 2020;142(19):8827–36.
Lu X, Zhu Y, Bai R, Wu Z, Qian W, Yang L, et al. Lengthy-term pulmonary publicity to multi-walled carbon nanotubes promotes breast most cancers metastatic cascades. Nat Nanotechnol. 2019;14(7):719–27.
Peng F, Setyawati MI, Tee JK, Ding X, Wang J, Nga ME, et al. Nanoparticles promote in vivo breast most cancers cell intravasation and extravasation by inducing endothelial leakiness. Nat Nanotechnol. 2019;14(3):279–86.
Chen C, Leong DT, Lynch I. Rethinking nanosafety: harnessing progress and driving Innovation. Small. 2020;16(21):2002503.
Chen C, Leong D, Lynch I. Rethinking nanosafety half II: leveraging progress to pioneer new approaches and options. Small. 2020;16(36):2004934.
Theurl I, Hilgendorf I, Nairz M, Tymoszuk P, Haschka D, Asshoff M, et al. On-demand erythrocyte disposal and iron recycling requires transient macrophages within the liver. Nature Med. 2016;22(8):945–51.
[ad_2]
